and the European Board for Accreditation in Cardiology (EBAC) to provide continuing medical education for physicians.
This work was funded by NIH grants HL135790, HL115103, and GM007347, American Heart Association grant 18PRE34070125, and NSF grants 1055384 and 2013170175. The datasets used for the analyses described were obtained from Vanderbilt University Medical Center's BioVU, which is supported by numerous sources: institutional funding, private agencies, and federal grants. These include the NIH-funded Shared Instrumentation grant S10RR025141, and CTSA grants UL1TR002243, UL1TR000445, and UL1RR024975. The clinical datasets used for the analyses described were obtained from Vanderbilt University Medical Center's Synthetic Derivative.
Dr. Lindman has received research grants from Edwards Lifesciences and Roche Diagnostics; served on scientific advisory boards for Roche Diagnostics; and has been a consultant to Medtronic and Roche Diagnostics. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
All authors attest they are in compliance with human studies committees and animal welfare regulations of the authors' Bowler et al.
Celecoxib Is Associated With Aortic Stenosis A P R I L 2 0 
METHODS IN VITRO EXPERIMENTS AND STATISTICAL ANALYSIS.
Porcine aortic valve cells were isolated as previously described (7, 13) and used between passages 3 and 11.
Cells were evaluated with a combination of molecular Medical Center
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Celecoxib Is Associated With Aortic Stenosis (10, 11) . In a separate cohort, AVICs were treated with conditioned medium harvested from AVEC cultures after strain. AVICs were also evaluated for contractility using a free-floating collagen gel system in which cells were plated onto gels and imaged over Bowler et al.
Celecoxib Is Associated With Aortic Stenosis University's institutional review board, and approval was given for this study.
RESULTS

IN VITRO DYSTROPHIC CALCIFICATION ANALYSIS.
Alizarin Red staining of calcium shows the characteristic rounded morphology of CNs formed by AVICs ( Figure 1A ). As expected, treatment with TGF-b1 increases the number of CNs under all pre-treatment conditions ( Figures 1A and 1B) . Unexpectedly, celecoxib pre-treatment causes a greater increase in CN number, whereas dimethyl celecoxib pre-treatment, as hypothesized, prevents TGF-b1-induced CN formation ( Figures 1A and 1B) . A gel contraction assay reveals that celecoxib-treated AVICs appear more contractile than their untreated or dimethyl celecoxib-treated counterparts, though not significantly ( Figure 1C) . TGF-b1 treatment increases contractility as well and compounds with celecoxib treatment to cause significantly more contraction than the no drug pre-treated with TGF-b1 ( Figure 1C) .
Expression of myofibroblast markers a-SMA and CDH11 were evaluated by Western blot ( Figures 1D and   1E , Supplemental Figure S1 ) and immunofluorescence Table S1 ) (16) . 
